Journal: Future oncology (London, England)
This publication reviews the treatment of hormone-sensitive prostate cancer (HSPC), focusing on therapies targeting the androgen-sensitive pathway.
It discusses:
- Patient identification and clinical reasoning behind different treatment approaches for metastatic and nonmetastatic HSPC.
- Current treatment options and potential barriers to optimal care.
- Strategies to balance disease control with preserving patient functionality and quality of life.
For patients with high-risk biochemical recurrence or metastatic HSPC, combination therapy with androgen deprivation and an androgen receptor pathway inhibitor is highlighted as the standard of care when appropriate.